TrianglePUBLICATIONS · 23276888
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Clin Lymphoma Myeloma Leuk
- Publication date
- 2013 Apr
- First author
- Westin JR
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Westin JR
- type
- Author
- name
- Thompson MA
- type
- Author
- name
- Cataldo VD
- type
- Author
- name
- Fayad LE
- type
- Author
- name
- Fowler N
- type
- Author
- name
- Fanale MA
- type
- Author
- name
- Neelapu S
- type
- Author
- name
- Samaniego F
- type
- Author
- name
- Romaguera J
- type
- Author
- name
- Shah J
- type
- Author
- name
- McLaughlin P
- type
- Author
- name
- Pro B
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Westin JR
- type
- Author
- name
- Thompson MA
- type
- Author
- name
- Cataldo VD
- type
- Author
- name
- Fayad LE
- type
- Author
- name
- Fowler N
- type
- Author
- name
- Fanale MA
- type
- Author
- name
- Neelapu S
- type
- Author
- name
- Samaniego F
- type
- Author
- name
- Romaguera J
- type
- Author
- name
- Shah J
- type
- Author
- name
- McLaughlin P
- type
- Author
- name
- Pro B
- type
- Author
- bibliography ids
- nci-bib-661eb304f09016c09d2363fa
- book metadata
- content sha256
- 7f2fa56c9a46108e28beb1f5642077110feb6a9015b1c38fe361a137c718524f
- document type
- citation
- dois
- 10.1016/j.clml.2012.11.002
- electronic publication date
- display
- 2012 Dec 29
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:23276888
- immutable id
- pubmed:23276888@7f2fa56c9a46108e28beb1f5642077110feb6a9015b1c38fe361a137c718524f
- journal
- abbreviation
- Clin Lymphoma Myeloma Leuk
- issn electronic
- 2152-2669
- issn print
- 2152-2650
- issue
- 2
- name
- Clinical lymphoma, myeloma & leukemia
- nlm unique id
- 101525386
- pages
- 99-105
- volume
- 13
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 23276888
- provenance
- batch id
- 99e85dbb34a1a3011c9a
- provider
- NCBI PubMed ESummary
- record sha256
- 67755d63483e29900bdb5c64a744cbce8c98ee14d3312ccf9be6e3a214b0fe86
- response sha256
- 1f4a46dcee9da36f8f58fe356dce3f44a1b3004f404e9fb0184f4e08aed4acf2
- retrieved at
- 2026-09-09T23:46:52.860383+00:00
- publication date
- display
- 2013 Apr
- precision
- month
- year
- 2013
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
Preserved source evidence · Independent clinical review pending · Not medical advice